3D Medicines Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
162
- Stock Symbol
-
01244
- Share Price
-
$0.33
- (As of Friday Closing)
3D Medicines General Information
Description
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
Contact Information
Website
www.3dmedcare.comCorporate Office
- Block A, Building 2, No.158 Xinjunhuan Road
- Pujiang Town, Minhang District
- Shanghai, 201114
- China
Corporate Office
- Block A, Building 2, No.158 Xinjunhuan Road
- Pujiang Town, Minhang District
- Shanghai, 201114
- China
3D Medicines Stock Performance
As of 13-Nov-2026, 3D Medicines’s stock price is $0.33. Its current market cap is $80.9M with 246M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.33 | $0.33 | $0.23 - $0.78 | $80.9M | 246M | 150K | -$0.10 |
3D Medicines Financials Summary
As of 30-Jun-2026, 3D Medicines has a trailing 12-month revenue of $51.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 31,553 | 116,297 | (3,438) | 163,452 |
| Revenue | 51,082 | 49,516 | 62,107 | 89,747 |
| EBITDA | (23,686) | (23,656) | (24,465) | (75,728) |
| Net Income | (24,782) | (24,687) | (25,457) | (74,163) |
| Total Assets | 138,015 | 133,812 | 166,608 | 201,575 |
| Total Debt | 25,225 | 21,836 | 32,550 | 39,842 |
3D Medicines Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
3D Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
3D Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
3D Medicines Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
3D Medicines ESG
Risk Overview
Risk Rating
Updated April, 30, 2024
32.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,744
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Pharmaceuticals
Subindustry
of 423
Rank
Percentile
3D Medicines Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Shuda Technology | Shanghai, China | 2023 |
3D Medicines FAQs
-
When was 3D Medicines founded?
3D Medicines was founded in 2010.
-
Where is 3D Medicines headquartered?
3D Medicines is headquartered in Shanghai, China.
-
What is the size of 3D Medicines?
3D Medicines has 162 total employees.
-
What industry is 3D Medicines in?
3D Medicines’s primary industry is Laboratory Services (Healthcare).
-
Is 3D Medicines a private or public company?
3D Medicines is a Public company.
-
What is 3D Medicines’s stock symbol?
The ticker symbol for 3D Medicines is 01244.
-
What is the current stock price of 3D Medicines?
As of 13-Nov-2026 the stock price of 3D Medicines is $0.33.
-
What is the current market cap of 3D Medicines?
The current market capitalization of 3D Medicines is $80.9M.
-
What is 3D Medicines’s current revenue?
The trailing twelve month revenue for 3D Medicines is $51.1M.
-
What is 3D Medicines’s annual earnings per share (EPS)?
3D Medicines’s EPS for 12 months was -$0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
